JP7505713B2 - アミロイドペプチドバリアント - Google Patents

アミロイドペプチドバリアント Download PDF

Info

Publication number
JP7505713B2
JP7505713B2 JP2021549163A JP2021549163A JP7505713B2 JP 7505713 B2 JP7505713 B2 JP 7505713B2 JP 2021549163 A JP2021549163 A JP 2021549163A JP 2021549163 A JP2021549163 A JP 2021549163A JP 7505713 B2 JP7505713 B2 JP 7505713B2
Authority
JP
Japan
Prior art keywords
iapp
hiapp
peptides
peptide
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521266A (ja
JP2022521266A5 (https=
Inventor
モフェット，デビッド
ノガジ，ルイザ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOYOLA MARYMOUNT UNIVERSITY
Mount Saint Mary's University
Original Assignee
LOYOLA MARYMOUNT UNIVERSITY
Mount Saint Mary's University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOYOLA MARYMOUNT UNIVERSITY, Mount Saint Mary's University filed Critical LOYOLA MARYMOUNT UNIVERSITY
Publication of JP2022521266A publication Critical patent/JP2022521266A/ja
Publication of JP2022521266A5 publication Critical patent/JP2022521266A5/ja
Priority to JP2024091172A priority Critical patent/JP7825238B2/ja
Application granted granted Critical
Publication of JP7505713B2 publication Critical patent/JP7505713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021549163A 2019-02-22 2020-02-24 アミロイドペプチドバリアント Active JP7505713B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091172A JP7825238B2 (ja) 2019-02-22 2024-06-05 アミロイドペプチドバリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809167P 2019-02-22 2019-02-22
US62/809,167 2019-02-22
PCT/US2020/019557 WO2020172686A1 (en) 2019-02-22 2020-02-24 Amyloid peptide variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091172A Division JP7825238B2 (ja) 2019-02-22 2024-06-05 アミロイドペプチドバリアント

Publications (3)

Publication Number Publication Date
JP2022521266A JP2022521266A (ja) 2022-04-06
JP2022521266A5 JP2022521266A5 (https=) 2022-11-14
JP7505713B2 true JP7505713B2 (ja) 2024-06-25

Family

ID=72145021

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021549163A Active JP7505713B2 (ja) 2019-02-22 2020-02-24 アミロイドペプチドバリアント
JP2024091172A Active JP7825238B2 (ja) 2019-02-22 2024-06-05 アミロイドペプチドバリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091172A Active JP7825238B2 (ja) 2019-02-22 2024-06-05 アミロイドペプチドバリアント

Country Status (6)

Country Link
US (2) US12522635B2 (https=)
EP (1) EP3927725A4 (https=)
JP (2) JP7505713B2 (https=)
CN (2) CN118955675A (https=)
IL (1) IL285699A (https=)
WO (1) WO2020172686A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021233942A1 (en) * 2020-05-19 2021-11-25 Empa Eidgenössische Materialprüfungs- Und Forschungsanstalt Detection and imaging of amyloid aggregates in blood

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
ATE514707T1 (de) * 2002-04-19 2011-07-15 Univ Toronto Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer
JP2007527365A (ja) * 2003-03-18 2007-09-27 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ アミリン凝集阻害剤およびその使用
DE102004051014A1 (de) * 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
GB0501348D0 (en) * 2005-01-24 2005-03-02 Zyentia Ltd Compositions and methods
AU2006341375B2 (en) * 2006-03-31 2013-03-21 Amylin Pharmaceuticals, Llc Amylin and amylin agonists for treating psychiatric diseases and disorders
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
US20130022620A1 (en) * 2011-06-09 2013-01-24 Ann Marie Schmidt Assays and methods pertaining to pre-amyloid intermediates
JP6121992B2 (ja) * 2011-06-10 2017-04-26 ノヴォ ノルディスク アー／エス ポリペプチド
US9475866B2 (en) * 2012-09-12 2016-10-25 Neurimmune Holding Ag Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
WO2015062803A1 (en) * 2013-10-29 2015-05-07 Kapurniotu Aphrodite Modified segments of islet amyloid polypeptide
CN108070075A (zh) * 2016-11-09 2018-05-25 可口可乐公司 生物基meg和聚酯纤维组合物以及制造它们的方法
WO2018144671A1 (en) * 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
WO2019241628A1 (en) * 2018-06-15 2019-12-19 Proclara Biosciences, Inc. General amyloid interaction motif (gaim)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IAPP isoform 3, partial [Pongo abelii]，Database GenBank [online], Accession No. PNJ86803.1，［令和５年９月１２日検索］，2018年01月19日，インターネット <URL : https://www.ncbi.nlm.nih.gov/protein/PNJ86803.1>
IAPP isoform 5, partial [Pan troglodytes]，Database GenBank［online］, Accession No. PNI98857.1，［令和５年９月１２日検索］，2018年01月19日，インターネット <URL : https://www.ncbi.nlm.nih.gov/protein/PNI98857.1>
J. AM. CHEM. SOC. ，2005年，Vol.127, No.45，15690-15691, Supporting Information

Also Published As

Publication number Publication date
JP2024125307A (ja) 2024-09-18
JP2022521266A (ja) 2022-04-06
US20220119468A1 (en) 2022-04-21
EP3927725A1 (en) 2021-12-29
US12522635B2 (en) 2026-01-13
WO2020172686A1 (en) 2020-08-27
US20260109744A1 (en) 2026-04-23
WO2020172686A9 (en) 2020-11-12
CN113614101B (zh) 2024-07-16
JP7825238B2 (ja) 2026-03-06
IL285699A (en) 2021-10-31
CN118955675A (zh) 2024-11-15
CN113614101A (zh) 2021-11-05
EP3927725A4 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
KR102508651B1 (ko) 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제
US20260109744A1 (en) Amyloid peptide variants
NZ587312A (en) Combination of alpha 7 nicotinic agonists and antipsychotics
TW202012628A (zh) 用於帕金森氏症治療的組成物及方法
JP2025090703A (ja) 糖尿病の処置のためのペプチド
JP2020023508A (ja) ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
JP2021525246A (ja) 心臓特異的標的化ペプチド（ｃｔｐ）、組成物およびその使用
Kelly et al. Neuronally derived soluble Abeta evokes cell-wide astrocytic calcium dysregulation in absence of amyloid plaques in vivo
KR20160088886A (ko) 자폐증 스펙트럼 장애의 치료에 사용되는 도파민 ｄ3 수용체 길항제로서의 크로모네 유도체
JP5579618B2 (ja) 治療および診断用化合物
WO2022212271A1 (en) Methods and compositions for treating lysosomal storage disorders
WO2025017057A1 (en) Peptides for use in the treatment of axonal damage in diabetes
JP6455983B2 (ja) アミロイド分解能を有する人工ペプチドおよびその利用
JP2018512411A (ja) アルツハイマー型認知症の治療および／または診断のための特定のａ−ベータ種に結合するペプチド
US6664297B1 (en) Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
WO2022239765A1 (ja) アミロイドβの凝集抑制剤、アミロイドβ凝集疾患用医薬組成物、およびその用途
EP4252750A1 (en) Pharmaceutical preservation of creb activation in the treatment of alzheimer&#39;s disease
EP4599842A1 (en) Pegylated gdf5 protein
KR20230054440A (ko) 심근 손상의 치료 또는 예방에 사용하기 위한 펩타이드
US20210169980A1 (en) Autophagy inhibitors
JPWO2005065703A1 (ja) ＧＰＲ１０３−ｌｉｋｅ受容体蛋白質に対するリガンドの新規用途
Cardoso Dynamics of transthyretin fibrillogenesis: contribution to therapeutic approaches in familial amyloidotic polyneuropathy
JP2008303144A (ja) アミロイド疾患の治療およびモニタリングのための薬剤
EA043417B1 (ru) АГОНИСТ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ GLP-1r КАК ТЕРАПИЯ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И НЕЙРОДЕГЕНЕРАТИВНЫХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ
JP2014141472A (ja) １，３，５−トリアジン誘導体を有する線維化予防又は治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240605